Navigation Links
3SBio Inc. Files for SFDA Approval of NuLeusin
Date:11/10/2008

SHENYANG, China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Administration (SFDA) for approval of NuLeusin for the treatment of late stage metastatic renal cell carcinoma. If approved, NuLeusin is expected to be the only treatment of this kind available in China.

NuLeusin, 3SBio's second-generation IL-2, is a genetically modified form of IL-2 possessing improved biochemical properties over naturally occurring IL-2. Clinical trials examined the safety and efficacy of two treatment cycles of subcutaneous injections of NuLeusin. During each six-week treatment cycle, patients were given daily doses of 7MIU/square meter in the induction phase and daily doses of 3.5MIU/square meter in the maintenance phase. The results showed an overall efficacy (Complete Response +Partial Response) of 12.73% and a disease control rate (Complete Response+ Partial Response+ Stable Disease) of 60%. Compared to Chiron's Proleukin, a treatment available in the United States, which is believed to be the only similar product on the market today, Nuleusin demonstrated similar levels of efficacy with a much lower dosage. More importantly, NuLeusin showed an improved safety and tolerability profile in patients who participated in the Phase III study.

"Today's submission comes only a little over one month following our submission for high dosage EPIAO and once again demonstrates our outstanding research and development capabilities and our strong ability to execute on our business plan," stated Dr. Jing Lou, Chief Executive Officer of 3SBio. "NuLeusin was developed to provide a new immunotherapy regimen for oncologists to treat patients with late stage metastatic renal cell carcinoma. Upon approval, we believe many patients who have exhausted their trea
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
2. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
3. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
4. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
5. 3SBio Inc. Announces Results of Annual General Meeting
6. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. Announces Second Quarter 2008 Results
9. 3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008
10. 3SBio Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
11. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MO (PRWEB) July 28, 2014 ... and services that bring the power of genomics to ... inaugural Appistry Pipeline Challenge . , Two ... president of the National Center for Genome Resources, and ... Hospitals and Clinics of Kansas City. Rounding out the ...
(Date:7/28/2014)... , July 28, 2014  InterMune, Inc. (NASDAQ: ... its second quarter 2014 financial results at the close ... live conference call and webcast will be hosted by ... Interested investors and others may participate in ... 212-231-2900 (international), conference ID#21728775. A replay of the webcast and ...
(Date:7/28/2014)... July 28, 2014 The National Model ... Muncie IN, is pleased to announce that it has ... Museum of the United States Air Force. , The ... process that concluded this spring with an on-site inspection ... OH museum. , The National Museum of the ...
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... approved a $500,000 start-up grant for the recently ... for classified, defense-related projects. , ,The consortium, ... initially include the UW System, the Medical College ... the Milwaukee School of Engineering. , ,The consortium ...
... Cisco Systems has reached an agreement ... local area network. , ,The UW-Madison campus serves 41,500 ... includes more than 180 buildings spread across 933 acres. ... can access a personalized window of their financial records, ...
... tiny man with giant ideas. Ill never forget the one and ... a conference of business executives in Cambridge, Massachusetts. There were one ... for a keynote, Drucker spoke immediately after lunch. He had to ... effortlessly for almost two hours. No Powerpoint. No props. No nonsense. ...
Cached Biology Technology:Wisconsin consortium aims for defense business 2Praise for the principles of Peter 2Praise for the principles of Peter 3Praise for the principles of Peter 4
(Date:7/28/2014)... Research Hospital study found that 73 percent of adult ... of developing metabolic syndrome and related health problems by ... in the current issue of the journal Cancer ... survivors of childhood cancer in the study had metabolic ... high blood pressure, abdominal obesity, elevated triglyceride and other ...
(Date:7/28/2014)... Brain & Behavior Research Foundation today announced the ... recognizing exceptional clinical and basic research by young ... Investigator Grants. The grants enable early career scientists ... research for the prevention, early detection, treatment, and ... four people. , Six young scientistswinners of the ...
(Date:7/28/2014)... Research and Markets has announced ... America 2014-2018" report to their offering. ... and analyze biological data. These systems capture biological traits ... patterns, and hand measurements from the subject and compare ... main purpose of a biometrics system is to identify ...
Breaking Biology News(10 mins):Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Biometrics Market in Latin America 2014-2018 2
... PLoS ONE highlights how the exploration of the ... of a voyage of discovery, starting with marine animals ... their application as marker in living cells. Many ... fluorescent proteins, which come in a variety of dazzling ...
... 30 Orchid Cellmark Inc.,(Nasdaq: ORCH ), a leading ... for the third quarter of 2008. , ... of 2008 compared,to $15.6 million for the third quarter of 2007. ... compared to a year ago was largely due,to lower revenues in ...
... 10 prominent scientists says that the level of globe-warming carbon ... where world climate will change disastrously unless the level can ... from recent estimates that truly dangerous levels would be reached ... the current edition of the Open Atmospheric Science Journal ...
Cached Biology News:Biomedical research profits from the exploration of the deep sea 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Orchid Cellmark Reports Third Quarter 2008 Financial Results 8Carbon dioxide already in danger zone, warns study 2
...
The large Dodeca stainer shaking rack holds the staining trays in the large Dodeca stainer....
... in this set of Antibody Microarray ... for a total of over 2100 ... internal control. Antibodies belonging to many ... cell cycle progression, signal transduction and ...
... is the most advanced thermal cycler ever ... performance, the Dyad also boasts graphical programming ... navigation via touch pad or mouse. ... economically expanded to a four-bay system with ...
Biology Products: